APA (7th ed.) Citation

Gutierrez, M., Winer, I. S., Reilley, M., Duska, L. R., Subbiah, V., Richardson, D. L., . . . Nevadunsky, N. (2025). A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors. Journal of clinical oncology, 43(5_suppl), TPS652. https://doi.org/10.1200/JCO.2025.43.5_suppl.TPS652

Chicago Style (17th ed.) Citation

Gutierrez, Martin, et al. "A Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 (claudin-6 X CD3) T-cell Engaging Bispecific Antibody in Subjects with Germ Cell Tumors and Other Advanced Solid Tumors." Journal of Clinical Oncology 43, no. 5_suppl (2025): TPS652. https://doi.org/10.1200/JCO.2025.43.5_suppl.TPS652.

MLA (9th ed.) Citation

Gutierrez, Martin, et al. "A Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 (claudin-6 X CD3) T-cell Engaging Bispecific Antibody in Subjects with Germ Cell Tumors and Other Advanced Solid Tumors." Journal of Clinical Oncology, vol. 43, no. 5_suppl, 2025, p. TPS652, https://doi.org/10.1200/JCO.2025.43.5_suppl.TPS652.